Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Short term Debt: 2020-2023

Historic Short term Debt for Zevra Therapeutics (ZVRA) over the last 2 years, with Dec 2023 value amounting to $37.7 million.

  • Zevra Therapeutics' Short term Debt was N/A to $37.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was $37.7 million, marking a year-over-year change of. This contributed to the annual value of $37.7 million for FY2023, which is N/A change from last year.
  • Zevra Therapeutics' Short term Debt amounted to $37.7 million in FY2023, which was up 9,566.67% from $390,000 recorded in FY2020.
  • Over the past 5 years, Zevra Therapeutics' Short term Debt peaked at $37.7 million during FY2023, and registered a low of $390,000 during FY2020.
  • Moreover, its 1-year median value for Short term Debt was $37.7 million (2023), whereas its average is $37.7 million.